Clinical Trial

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Study acronym: TRAVERSE
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-01-04; most recent amendment 2026-07-16.
Status change: Recruiting → Active, Not Recruiting 2025-09-22
Status change: Active, Not Recruiting → Recruiting 2022-02-09
Status change: Recruiting → Active, Not Recruiting 2021-10-13
Status change: Not Yet Recruiting → Recruiting 2021-03-26
Trial Details
NCT Number NCT04696731
Lead Sponsor Allogene Therapeutics
Conditions Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Enrollment 120 participants
Start Date 2021-02-24
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17